Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03816332
Title Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

basal cell carcinoma

skin squamous cell carcinoma

Merkel cell carcinoma

Advanced Solid Tumor

melanoma

Therapies

Ipilimumab + Nivolumab + Prednisone + Tacrolimus

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.